PE20000241A1 - PHARMACEUTICAL COMPOSITION OF HEDGEHOG PROTEINS AND USE OF THE SAME - Google Patents
PHARMACEUTICAL COMPOSITION OF HEDGEHOG PROTEINS AND USE OF THE SAMEInfo
- Publication number
- PE20000241A1 PE20000241A1 PE1999000072A PE00007299A PE20000241A1 PE 20000241 A1 PE20000241 A1 PE 20000241A1 PE 1999000072 A PE1999000072 A PE 1999000072A PE 00007299 A PE00007299 A PE 00007299A PE 20000241 A1 PE20000241 A1 PE 20000241A1
- Authority
- PE
- Peru
- Prior art keywords
- contain
- protein
- support
- pharmaceutical composition
- erizo
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003693 Hedgehog Proteins Human genes 0.000 title 1
- 108090000031 Hedgehog Proteins Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 abstract 2
- 150000002500 ions Chemical class 0.000 abstract 2
- 229920000936 Agarose Polymers 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 241000027355 Ferocactus setispinus Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229920001586 anionic polysaccharide Polymers 0.000 abstract 1
- 150000004836 anionic polysaccharides Chemical class 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000013020 embryo development Effects 0.000 abstract 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA PROTEINA ERIZO (HEDGEHOG) UNIDA A UN SOPORTE HIDROFILICO BIOCOMPATIBLE Y BIODEGRADABLE, UTILIZANDOSE DE 0,1 mg/ml A 100 mg/ml. EL SOPORTE ES UN POLIMERO QUE SE CARACTERIZA a)POR SER UN ANION A CAUSA DE INTERACCIONES IONICAS; b)NO DESNATURALIZAR LA PROTEINA; c)CONTENER DE 0,1 A 2 IONES POR MONOMERO EN CONDICIONES NEUTRAS; d)CONTENER CARGAS EN FORMA DE GRUPOS DE CARACTER ACIDO; e)PESO MOLECULAR DE 50 000 DALTON; f)NO CONTENER AGAROSA. EL SOPORTE SE COMPONE DE UNA MATRIZ ORGANICA DE SOPORTE HIDROFILICO (ACIDO HIALURONICO) O UN POLISACARIDO ANIONICO O ACIDO HIALURONICO O DE UN FOSFATO INORGANICO INSOLUBLE. LA COMPOSICION SE CARACTERIZA POR EL pH DE 4-10; Y ADICIONALMENTE PUEDE CONTENER ARGININA O IONES ARGINILO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LA PROTEINA ERIZO ES RESPONSABLE DE LA FORMACION DE ESTRUCTURAS EN LA EMBRIOGENESIS Y SE LIBERA EN FORMA LOCAL EN HUESOS Y CARTILAGOSIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ERIZO PROTEIN (HEDGEHOG) UNITED TO A BIOCOMPATIBLE AND BIODEGRADABLE HYDROPHILIC SUPPORT, USING FROM 0.1 mg / ml TO 100 mg / ml. THE SUPPORT IS A POLYMER THAT IS CHARACTERIZED a) FOR BEING AN ANION AS A CAUSE OF IONIC INTERACTIONS; b) DO NOT DENATURALIZE THE PROTEIN; c) CONTAIN FROM 0.1 TO 2 IONS PER MONOMER IN NEUTRAL CONDITIONS; d) CONTAIN LOADS IN THE FORM OF GROUPS OF ACID CHARACTER; e) MOLECULAR WEIGHT OF 50,000 DALTON; f) DO NOT CONTAIN AGAROSE. THE SUPPORT IS COMPOSED OF AN ORGANIC MATRIX OF HYDROPHILIC SUPPORT (HYALURONIC ACID) OR AN ANIONIC POLYSACCHARIDE OR HYALURONIC ACID OR OF AN INSOLUBLE INORGANIC PHOSPHATE. THE COMPOSITION IS CHARACTERIZED BY THE pH OF 4-10; AND ADDITIONALLY IT MAY CONTAIN ARGININE OR ARGINYL IONS. IT ALSO REFERS TO A PROCEDURE FOR PREPARATION. ERIZO PROTEIN IS RESPONSIBLE FOR THE FORMATION OF STRUCTURES IN EMBRYOGENESIS AND IS RELEASED LOCALLY IN BONES AND CARTILAGES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98101893 | 1998-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000241A1 true PE20000241A1 (en) | 2000-04-08 |
Family
ID=8231349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000072A PE20000241A1 (en) | 1998-02-04 | 1999-02-01 | PHARMACEUTICAL COMPOSITION OF HEDGEHOG PROTEINS AND USE OF THE SAME |
Country Status (8)
| Country | Link |
|---|---|
| AR (1) | AR014530A1 (en) |
| BR (1) | BR9900523A (en) |
| HR (1) | HRP990036A2 (en) |
| ID (1) | ID22356A (en) |
| PE (1) | PE20000241A1 (en) |
| PL (1) | PL331201A1 (en) |
| TR (1) | TR199900197A2 (en) |
| ZA (1) | ZA99887B (en) |
-
1999
- 1999-02-01 PE PE1999000072A patent/PE20000241A1/en not_active Application Discontinuation
- 1999-02-02 AR ARP990100423 patent/AR014530A1/en unknown
- 1999-02-02 TR TR1999/00197A patent/TR199900197A2/en unknown
- 1999-02-02 ID IDP990071D patent/ID22356A/en unknown
- 1999-02-03 PL PL33120199A patent/PL331201A1/en unknown
- 1999-02-03 HR HRP990036 patent/HRP990036A2/en not_active Application Discontinuation
- 1999-02-03 BR BR9900523-9A patent/BR9900523A/en not_active IP Right Cessation
- 1999-02-04 ZA ZA9900887A patent/ZA99887B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HRP990036A2 (en) | 1999-08-31 |
| BR9900523A (en) | 2000-05-02 |
| ID22356A (en) | 1999-10-07 |
| ZA99887B (en) | 1999-08-04 |
| AR014530A1 (en) | 2001-02-28 |
| PL331201A1 (en) | 1999-08-16 |
| TR199900197A2 (en) | 1999-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arakawa et al. | Photopolymerizable chitosan–collagen hydrogels for bone tissue engineering | |
| Chenite et al. | Novel injectable neutral solutions of chitosan form biodegradable gels in situ | |
| Xu et al. | Heparin-decorated, hyaluronic acid-based hydrogel particles for the controlled release of bone morphogenetic protein 2 | |
| EP2106263B1 (en) | Water soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof | |
| Mohandas et al. | Chitosan–hyaluronic acid/VEGF loaded fibrin nanoparticles composite sponges for enhancing angiogenesis in wounds | |
| Thomopoulos et al. | bFGF and PDGF-BB for tendon repair: controlled release and biologic activity by tendon fibroblasts in vitro | |
| Park et al. | Injectable chitosan hyaluronic acid hydrogels for cartilage tissue engineering | |
| Tianyuan et al. | A smart MMP13‐responsive injectable hydrogel with inflammatory diagnostic logic and multiphase therapeutic ability to orchestrate cartilage regeneration | |
| EP2324065B1 (en) | A heparan sulphate which binds bmp2 | |
| Abbah et al. | In vivo bioactivity of rhBMP-2 delivered with novel polyelectrolyte complexation shells assembled on an alginate microbead core template | |
| Matricardi et al. | Polysaccharide hydrogels: Characterization and biomedical applications | |
| BRPI0416590A (en) | excipients in drug delivery vehicles | |
| BRPI0416032A (en) | excipients in drug delivery vehicles | |
| KR20040047746A (en) | Improved bone graft | |
| RU2012122334A (en) | COMPOSITION OF POLYSACCHARID GEL POSSESSING MULTISTAGE DELIVERY OF BIOACTIVE SUBSTANCES | |
| KR20150131329A (en) | Low molecular weight silk compositions and stabilizing silk compositions | |
| BRPI0411678A (en) | nanoparticles of hyaluronic acid | |
| WO2010040865A1 (en) | New biomaterial based on wharton's jelly from the human umbilical cord | |
| AU4344899A (en) | Pharmaceutical composition of hedgehog proteins and use thereof | |
| Thankam et al. | Hybrid interpenetrating hydrogel network favoring the bidirectional migration of tenocytes for rotator cuff tendon regeneration | |
| Wu et al. | Development of a chitosan–polyglutamate based injectable polyelectrolyte complex scaffold | |
| Cardoso et al. | Bifunctional naringenin-laden gelatin methacryloyl scaffolds with osteogenic and anti-inflammatory properties | |
| Przekora et al. | Chitosan/β-1, 3-glucan/hydroxyapatite bone scaffold enhances osteogenic differentiation through TNF-α-mediated mechanism | |
| WO2021042777A1 (en) | Multi-component gel sustained-release pharmaceutical composition for treatment of tumors | |
| SE9603480L (en) | Dosage form for hard soluble drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |